Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.34 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988920 | 0.86 | OXER1 (0.42) | OXER1KMONOTUMCCR2SLC22A12 | |
| SCHEMBL4052956 | 0.80 | DAO (0.37) | OXER1CYP11B1CYP11B2NOTUMTFPI2 | |
| SCHEMBL5634574 | 0.77 | HTR2A (0.46) | OXER1KMOCCR2SLC22A12TFPI2 | |
| SCHEMBL27548082 | 0.76 | ALKBH5 (0.36) | CYP11B1CYP11B2NOTUMTFPI2 | |
| SCHEMBL4045901 | 0.76 | OXER1 (0.39) | OXER1KMOCCR2SLC22A12TFPI2 | |
| SCHEMBL28661724 | 0.74 | OXER1 (0.63) | OXER1KMOMCL1NOTUMCCR2 | |
| SCHEMBL6901863 | 0.74 | TFPI2 (0.55) | OXER1CYP11B1CYP11B2NOTUMTFPI2 | |
| SCHEMBL5622574 | 0.74 | FABP4 (0.45) | OXER1KMONOTUMTFPI2TSHR | |
| SCHEMBL2659180 | 0.74 | OXER1 (0.63) | OXER1KMONOTUMCCR2TSHR | |
| SCHEMBL18876201 | 0.73 | PRKCI (0.50) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589097-B2 | Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-09-25 | — | — | US | disclosed |
| US-7405219-B2 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2007-03-01 | — | — | US | disclosed |
| US-7141575-B2 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | OXER1 358/4885KMO 505/4885CYP11B1 2034/4885 |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | OXER1 307/4885KMO 451/4885CYP11B1 1727/4885 |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | OXER1 501/4885KMO 361/4885CYP11B1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.